The impact of menstrual side effects on contraceptive discontinuation: Findings from a longitudinal study in Cairo, Egypt

International Family Planning Perspectives

Volumn 31, Issue 1, 2005, Pages 15-23

  Tolley, Elizabeth ^a   Loza, Sarah ^b   Kafafi, Laila ^a   Cummings, Stirling ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b Social Planning Analysis and Administration Consultants   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT;

CONTRACEPTIVE USE;

ADULT; ARTICLE; EGYPT; FEMALE; HUMAN; INFORMATION PROCESSING; INTRAUTERINE CONTRACEPTIVE DEVICE; LONGITUDINAL STUDY; MENSTRUATION DISORDER; QUESTIONNAIRE; SEXUAL BEHAVIOR; STATISTICAL MODEL;

ADULT; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; EGYPT; FEMALE; FOCUS GROUPS; HUMANS; INTRAUTERINE DEVICES; LONGITUDINAL STUDIES; MENSTRUATION DISTURBANCES; MODELS, STATISTICAL; QUESTIONNAIRES;

AFRICA; CAIRO [CAIRO (GVR)]; CAIRO [EGYPT]; EASTERN HEMISPHERE; EGYPT; NORTH AFRICA; WORLD;

EID: 17644382413     PISSN: 01903187     EISSN: None     Source Type: Journal    
DOI: 10.1363/3101505     Document Type: Article

References (38)

1. Paul C, Skegg D and Williams S, Depot medroxyprogesterone acetate: patterns of use and reasons for discontinuation, Contraception, 1997, 56(4):209-214;
2. Fleming D, Davie J and Glasier A, Continuation rates of long-acting methods of contraception, Contraception, 1998, 57(1):19-21;
3. Sivin I et al., Levonorgestrel capsule implants in the United States: a 5-year study, Obstetrics & Gynecology, 1998, 92(3):337-344;
4. and Stewart GK, Intrauterine devices (IUDs), in: Hatcher RA et al., eds., Contraceptive Technology, 17th ed., New York: Ardent Media, 1998, pp. 511-543.
5. Rivera R, Chen-Mok M and McMullen S, Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD, Contraception, 1999, 60(3):155-160;
6. Hubacher D et al., Factors affecting continuation rates of DMPA, Contraception, 1999, 60(6):345-351;
7. and Tolley E and Nare C, Access to Norplant removal: an issue of informed consent, African Journal of Reproductive Health, 2001, 5(1):90-99.
8. Trieman KL et al., IUDs-an update, Population Reports, 1995, Series B, No. 6.
9. Hatcher RA, Depo-Provera injections, implants, and progestin-only pills (minipills), in: Hatcher RA et al., eds., Contraceptive Technology, 18th ed., New York: Irvington Publishers, 2004.
10. Paul C, Skegg D and Williams S, 1997, op. cit. (see reference 1).
11. Gray RH, Parker RA and Biethelm P, Vaginal bleeding disturbances associated with discontinuation of long-acting injectable contraceptives, British Journal of Obstetrics and Gynaecology, 1981, 88(3):317-321.
12. Dunson TR, Krueger SL and Amatya RN, Risk factors for discontinuation of Norplant implant use due to menstrual problems, Advances in Contraception, 1996, 12(3):201-212;
13. and Sivin I et al., 1998, op. cit. (see reference 1).
14. Fraser IS et al., A detailed analysis of menstrual blood loss in women using Norplant and nestorone progestogen-only contraceptive implants or vaginal rings, Contraception, 2000, 61(4):241-251.
15. Hassan EO, El-Nahal N and El-Husseini M, Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt, Contraception, 1999, 60(2):87-92.
16. Gray RH, Parker RA and Biethelm P, 1981, op. cit. (see reference 6).
17. Datey S, Gaur LN and Saxena BN, Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)-an Indian experience, Contraception, 1995, 51(3):155-165;
18. and Fleming D, Davie J and Glasier A, 1998, op. cit. (see reference 1).
19. World Health Organization Task Force on Psychosocial Research n Family Planning, Special Programme of Research, and Development and Research Training in Human Reproduction, A cross-cultural study of menstruation: implications for contraceptive development and use, Studies in Family Planning, 1981, 12(1):3-16.
20. Rivera R, Chen-Mok M and McMullen S, 1999, op. cit. (see reference 2).
21. Tolley E and Nate C, 2001, op. cit. (see reference 2).
22. Hubacher D et al., 1999, op. cit. (see reference 2).
23. Wafai and Associates, Division of Research and Communication, Report on Expanding Injectable Use-A Diagnostic Study, Giza, Egypt: Wafai and Associates, 1996, pp. 1-66.
24. Tolley E and Nare C, 2001, op. cit. (see reference 2).
25. Bruce J, Fundamental elements of the quality of care: a simple framework, Studies in Family Planning, 1990, 21(2):61-91.
26. Lei ZW et al., Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception, Contraception, 1996, 53(6):357-361;
27. Hubacher D et al., 1999, op. cit. (see reference 2);
28. and Canto De Cetina TP, Canto P and Ordonez LM, Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate, Contraception, 2001, 63(3):143-146.
29. McCauley AP and Geller JS, Decisions for Norplant programs, Population Reports, 1992, Series K, No. 4.
30. Belsey EM, Machin D and d'Arcangues C, The analysis of vaginal bleeding patterns induced by fertility regulating methods, Contraception, 1986, 34(3):235-260.
31. Belsey EM, Pinol APY and the Task Force on Long-Acting Systemic Agents for Fertility Regulation, Menstrual bleeding patterns in untreated women, Contraception, 1997, 55(2):57-65.
32. Trieman KL et al., 1995, op. cit. (see reference 3);
33. and Hatcher RA et al., 1998, op. cit. (see reference 4).
34. McCauley AP and Geller JS, 1992, op. cit. (see reference 20).
35. Nutley T and Dunson TR, Treatment of bleeding problems associated with progestin-only contraceptives: survey results, Advances in Contraception, 1997, 13(4):419-428.
36. Hubacher D et al., 1999, op. cit. (see reference 2);
37. and Tolley E and Nare C, 2001, op. cit. (see reference 2).
38. Lei ZW et al., 1996, op. cit. (see reference 19).